Similar articles for PMID: 20953324

Year	Number of Results
1989	2
1990	4
1991	5
1992	6
1993	3
1994	3
1995	4
1996	2
1997	1
1998	1
1999	1
2000	1
2001	1
2003	3
2004	3
2005	1
2007	1
2008	3
2009	2
2010	4
2011	3
2012	6
2013	6
2014	8
2015	8
2016	7
2017	7
2018	9
2019	3
2020	5
2021	7
2022	9
2024	0

1

Overview of cellular immunotherapy for patients with glioblastoma.

Vauleon E, Avril T, Collet B, Mosser J, Quillien V. Vauleon E, et al. Clin Dev Immunol. 2010;2010:689171. doi: 10.1155/2010/689171. Epub 2010 Oct 4. Clin Dev Immunol. 2010. PMID: 20953324 Free PMC article. Review.

2

Clinical trials with immunotherapy for high-grade glioma.

Ruzevick J, Jackson C, Phallen J, Lim M. Ruzevick J, et al. Neurosurg Clin N Am. 2012 Jul;23(3):459-70. doi: 10.1016/j.nec.2012.04.003. Epub 2012 Jun 8. Neurosurg Clin N Am. 2012. PMID: 22748658 Review.

3

Cellular immunotherapy for high-grade glioma.

Chow KH, Gottschalk S. Chow KH, et al. Immunotherapy. 2011 Mar;3(3):423-34. doi: 10.2217/imt.10.110. Immunotherapy. 2011. PMID: 21395383 Free PMC article.

4

Passive immunotherapeutic strategies for the treatment of malignant gliomas.

Nagasawa DT, Fong C, Yew A, Spasic M, Garcia HM, Kruse CA, Yang I. Nagasawa DT, et al. Neurosurg Clin N Am. 2012 Jul;23(3):481-95. doi: 10.1016/j.nec.2012.04.008. Neurosurg Clin N Am. 2012. PMID: 22748660 Free PMC article. Review.

5

HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.

Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S. Ahmed N, et al. Clin Cancer Res. 2010 Jan 15;16(2):474-85. doi: 10.1158/1078-0432.CCR-09-1322. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068073 Free PMC article.

6

Immunotherapy for glioma: promises and challenges.

Han SJ, Zygourakis C, Lim M, Parsa AT. Han SJ, et al. Neurosurg Clin N Am. 2012 Jul;23(3):357-70. doi: 10.1016/j.nec.2012.05.001. Neurosurg Clin N Am. 2012. PMID: 22748649 Review.

7

Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme.

Bregy A, Wong TM, Shah AH, Goldberg JM, Komotar RJ. Bregy A, et al. Cancer Treat Rev. 2013 Dec;39(8):891-907. doi: 10.1016/j.ctrv.2013.05.007. Epub 2013 Jun 21. Cancer Treat Rev. 2013. PMID: 23790634 Review.

8

Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J. Hayes RL, et al. Cancer. 1995 Sep 1;76(5):840-52. doi: 10.1002/1097-0142(19950901)76:5<840::aid-cncr2820760519>3.0.co;2-r. Cancer. 1995. PMID: 8625188

9

Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.

Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, Sharp SL, DePriest MC. Dillman RO, et al. J Immunother. 2009 Nov-Dec;32(9):914-9. doi: 10.1097/CJI.0b013e3181b2910f. J Immunother. 2009. PMID: 19816190 Clinical Trial.

10

Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.

Poli A, Wang J, Domingues O, Planagumà J, Yan T, Rygh CB, Skaftnesmo KO, Thorsen F, McCormack E, Hentges F, Pedersen PH, Zimmer J, Enger PØ, Chekenya M. Poli A, et al. Oncotarget. 2013 Sep;4(9):1527-46. doi: 10.18632/oncotarget.1291. Oncotarget. 2013. PMID: 24127551 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

118 results

Results by year